Paladin Labs: Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada
Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced that the Company has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc ("Endo") (NASDAQ: ENDP), to register, commercialize, and distribute abaloparatide on an exclusive basis in Canada
Read full article »
Paladin Labs is a pharmaceutical company focused on developing, acquiring, in-licensing, marketing and distributing pharmaceutical products.
Read more